Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 Q575del |
Therapy | Cytarabine + Daunorubicin + Gilteritinib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 Q575del | acute myeloid leukemia | predicted - sensitive | Cytarabine + Daunorubicin + Gilteritinib | Case Reports/Case Series | Actionable | In a clinical case study, induction therapy with Cytosar-U (cytarabine) and Cerubidine (daunorubicin) combined with Xospata (gilteritinib) resulted in complete remission in a patient with acute myeloid leukemia harboring FLT3 Q575del (PMID: 33914060). | 33914060 |
PubMed Id | Reference Title | Details |
---|---|---|
(33914060) | Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. | Full reference... |